Ataluren (Translarna, PTC Therapeutics) has a conditional marketing authorisation for 'the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older'.
The company has a commercial arrangement. This makes ataluren available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.